Successful colonoscopic fecal transplant for severe acute Clostridium difficile pseudomembranous colitis

Gallegos-Orozco JF,1 Paskvan-Gawryletz CD,2 Gurudu SR,1 Orenstein R.3

Received December 5th, 2011; accepted January 10th, 2012.

Keywords: Fecal bacteriotherapy, fecal replacement therapy, infectious colitis, Clostridium difficile-associated diarrhea, USA.

Trasplante fecal colonoscópico exitoso en colitis pseudomembranosa grave por Clostridium difficile.

Correspondence author: Juan F. Gallegos-Orozco, M.D. Assistant Professor of Medicine, Mayo College of Medicine. Division of Hepatology, Mayo Clinic in Arizona 5777 E Mayo Blvd., Phoenix, AZ. Z.P. 85054. Telephone: 480 342 1010. E-mail: gallegos.juan@mayo.edu

0375-0906/$ - see front matter © 2012 Asociación Mexicana de Gastroenterología. Publicado por Elsevier México. Todos los derechos reservados.
Introduction

*Clostridium difficile* colitis has become one of the most common healthcare-associated infections and a significant contributor to morbidity and mortality, especially among elderly hospitalized patients. We describe our successful experience with colonoscopic fecal transplant in a case of severe refractory *C. difficile* pseudomembranous colitis.

Case presentation

A 71-year-old man with peripheral vascular disease developed severe diarrhea after receiving several antimicrobials for a femoral popliteal graft surgical site infection. He was admitted with profuse watery diarrhea, dehydration, leukocytosis, acute kidney injury, hypoalbuminemia and diffuse colonic wall thickening on CT scan. *Clostridium difficile* toxin assay by PCR using the commercially available Xpert®, *C. difficile* assay by Cepheid® (Sunnyvale, CA), which detects three targets: toxin B, binary toxin and the *tdcC* deletion, was positive. Oral metronidazole (500 mg every six hours) was commenced. Due to lack of clinical improvement 48 hours later the treatment was switched to oral vancomycin (125 mg every six hours) combined with parenteral metronidazole (500 mg IV every eight hours). In spite of this regimen his stool output remained greater than 1,000 mL/day. Flexible sigmoidoscopy on hospital day 8, showed severe pseudomembranous colitis and the oral vancomycin dose was increased to 500 mg every six hours. After three days at this dose he continued having profuse diarrhea and was given 400 mg/Kg IV immune globulin (IVIG) and IV tigecycline thereafter. The patient's consent, all the antimicrobials were stopped the night prior to fecal replacement therapy. Colonoscopy on hospital day 18 revealed persistence of pseudomembranous colitis from the rectum to the distal transverse colon (*Figure 1*). Fresh donor stool was homogenized in 400 mL of normal saline and was administered endoscopically throughout the colon. On day three post-fecal replacement, the patient's diarrhea and abdominal pain resolved and he was dismissed following a 24-day hospitalization and remains clinically well at 30 days post-discharge with normal bowel movements.

Discussion

Fecal replacement therapy, also known as fecal bacteriotherapy or fecal transplantation, has been increasingly used for the management of recurrent *C. difficile* infection with numerous case series reporting successful outcomes in 73% to 100% of cases. Fecal replacement has variably been accomplished via nasogastric tube infusion, retention enemas, duodenoscopic and colonoscopic infusion. The management of severe refractory *C. difficile* infection remains problematic and despite recent guidelines there is little evidence to support management recommendations. Most patients receive high doses of oral vancomycin and IV metronidazole. Prior reports suggest benefit to IVIG.
and IV tigecycline. All of these were tried unsuccess-fully in our patient. To our knowledge, this is only the second case report of successful fecal bacteriotherapy in the setting of severe, refractory *C. difficile* colitis, and the first one to use a colonoscopic approach to fecal implantation in this setting. In the first report, the patient had fulminant *C. difficile* colitis that resolved after donor stool retention enema. Our patient, like many others with this disease, was desperate for a non-operative solution after over two weeks of hospitalization and ineffective treatments. The striking response after discontinuing all therapy for *C. difficile* and providing the brother’s fecal flora suggests this may be an alternative treatment for severe and refractory disease as well as recurrent disease. Although we cannot be certain that his improvement wasn’t a cumulative impact of all the previous treatments, the dramatic clinical response after stopping all *C. difficile* therapies suggests that it was the fecal replacement that provided the cure. Risks of colonoscopy should be considered while deciding the route of fecal replacement therapy, particularly in patients with severe colitis. Our findings suggest this intervention warrants further study regarding not only the clinical benefits but the safety, logistics and mechanism by which this colon saving procedure may work.

**Sources of support.** No financial support was provided to the authors for this work.

**Disclosures.** No conflicts of interest to disclose.

**References**